eXmoor, Siam Bioscience Partner to Establish CGT Services in Southeast Asia

eXmoor Pharma, an integrated cell and gene therapy CDMO, and Siam Bioscience, a biopharmaceutical company based in ASEAN, have partnered to build a center for Cell and Gene Therapy (CGT) development and manufacturing in Thailand.

The collaboration aims to stimulate and accelerate the growth of the CGT industry in Thailand and Southeast Asia. Based in Bangkok, the new offering will serve therapy developers working to deliver advanced medicines to patients more efficiently and in full regulatory compliance.

Under the partnership, eXmoor will work jointly with Siam Bioscience to provide a full range of services, including consultancy, process and analytical development, and GMP clinical and commercial manufacturing. The new center will be located at Siam Bioscience’s manufacturing site near Bangkok, with both companies contributing their respective expertise and infrastructure to the initiative.

The partnership also aims to act as a platform to introduce international cell and gene therapies and technologies into the region. This will give patients across Southeast Asia greater access to international standard CGT, while supporting the growth of sustainable healthcare systems in the region. By offering a regionally based but globally aligned manufacturing model, the collaboration aims to reduce delays, lower logistic burdens, and improve equity of access to transformative therapies.

Angela Osborne, Executive Chair of eXmoor Pharma, said, “By combining Siam Bioscience’s regional leadership with eXmoor’s technical expertise and global CDMO capabilities, we are creating a launchpad to support both local breakthroughs and international partnerships. This is about bringing life-changing therapies to more patients, more quickly, and with the right infrastructure to support long-term success.”

Songpon Deechongkit, CEC at Siam Bioscience, remarked, “Partnering with eXmoor Pharma allows us to leverage its track record of supporting and growing successful CGT companies and programs over the past 20 years to advance cell and gene therapy in our region. Our CGT center will not only enable access to established products but also support translational research in Thailand and neighboring countries, with a focus on practical commercialization in line with international standards.  These efforts will strengthen Thailand’s position as a medical hub for the ASEAN region.”